Amneal Pharma Europe

Company snapshot

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is guided by a simple belief: essential medicines should be accessible to everyone. What began as a promise to deliver high-quality, affordable medicines has evolved into a diversified portfolio spanning complex generics and injectables, biosimilars, and specialty medicines, including more than 290 products, with scale and capabilities that help reach pa

• 211 approved product(s) across US/EU regulatory metadata.
• 15 active pipeline program(s) linked via ClinicalTrials.gov.
• 32 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Amneal Pharma Europe. Not investment advice.

• approval Jun 6, 2026

  Amneal Romidepsin FDA Approval: B2B Analysis for BD Teams and Investors

• Peer + 0 momentum

  Teva Pharma

  TA overlap score 50

• Peer + 0 momentum

  Jazz Pharmaceuticals Ireland

  TA overlap score 40

• Peer + 0 momentum

  Sunshine Guojian Pharmaceutical

  TA overlap score 40

• Peer + 0 momentum

  Boehringer Ingelheim

  TA overlap score 40

• Peer + 0 momentum

  Indivior Pty

  TA overlap score 27.8

• Peer + 0 momentum

  Acadia Pharmaceuticals

  TA overlap score 26.4

• Peer + 0 momentum

  Grace Therapeutics

  TA overlap score 25.8

• Peer + 0 momentum

  H. Lundbeck A/S

  TA overlap score 23.4

• Peer + 0 momentum

  Mundipharma

  TA overlap score 20.8

Recent activity

Latest pipeline, patent, and corporate events for Amneal Pharma Europe.

1. Jun 8, 2026 Clinical update

   AM-PHN-004 — Phase 3

2. Jun 8, 2026 Clinical update

   Test - Bimatoprost 0.01% Ophthalmic Solution — Phase 3

3. Jun 8, 2026 Clinical update

   Phenazopyridine Hydrochloride — Phase 3

4. Jun 8, 2026 Clinical update

   Mometasone Furoate Nasal Spray, 50 mcg — Phase 3

5. Jun 8, 2026 Clinical update

   Imatinib Mesylate Tablets, 400 mg — Phase 3

View all clinical trial activity →

• What is Amneal Pharma Europe?

  Amneal Pharma Europe is a pharma organization headquartered in Bridgewater, USA. It trades on NYSE under ticker AMRX. Primary therapeutic focus areas include Asthma, Osteoarthritis, Schizophrenia, Open-angle Glaucoma, Parkinson Disease. NovaPharmaNews links 15 clinical program(s)

• Is Amneal Pharma Europe publicly traded?

  Yes. Amneal Pharma Europe is listed with ticker AMRX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Amneal Pharma Europe develop or market?

  We link 210 drug profile(s) where Amneal Pharma Europe is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/amneal-pharmaceuticals#company-drugs.

• What are the latest developments for Amneal Pharma Europe?

  In the last 12 months our linked public records show 15 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does Amneal Pharma Europe focus on?

  Amneal Pharma Europe focuses on Asthma, Osteoarthritis, Schizophrenia based on our analysis of their pipeline programs and drug development activities.